I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| cardiac muscle cell | 3 studies | 19% ± 2% | |
| glutamatergic neuron | 3 studies | 23% ± 2% | |
| transit amplifying cell | 3 studies | 30% ± 11% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| cardiac muscle cell | 3 studies | 19% ± 2% | |
| glutamatergic neuron | 3 studies | 23% ± 2% | |
| transit amplifying cell | 3 studies | 30% ± 11% |
Insufficient scRNA-seq data for expression of LIN9 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| ovary | 100% | 327.77 | 180 / 180 | 100% | 10.04 | 430 / 430 |
| esophagus | 100% | 222.86 | 1443 / 1445 | 100% | 11.27 | 183 / 183 |
| breast | 100% | 222.06 | 458 / 459 | 99% | 10.72 | 1107 / 1118 |
| uterus | 100% | 242.64 | 170 / 170 | 98% | 12.78 | 450 / 459 |
| intestine | 100% | 240.48 | 964 / 966 | 97% | 8.03 | 510 / 527 |
| bladder | 100% | 177.57 | 21 / 21 | 96% | 7.42 | 486 / 504 |
| stomach | 99% | 205.03 | 357 / 359 | 97% | 8.77 | 277 / 286 |
| lung | 97% | 177.13 | 560 / 578 | 99% | 9.23 | 1147 / 1155 |
| brain | 98% | 173.27 | 2576 / 2642 | 95% | 5.13 | 667 / 705 |
| skin | 100% | 354.25 | 1806 / 1809 | 87% | 6.61 | 412 / 472 |
| thymus | 99% | 170.22 | 649 / 653 | 84% | 3.84 | 508 / 605 |
| pancreas | 93% | 97.81 | 305 / 328 | 89% | 4.25 | 159 / 178 |
| prostate | 100% | 177.89 | 245 / 245 | 78% | 3.04 | 393 / 502 |
| kidney | 94% | 117.35 | 84 / 89 | 67% | 2.47 | 601 / 901 |
| adrenal gland | 97% | 159.89 | 250 / 258 | 41% | 1.50 | 95 / 230 |
| liver | 78% | 64.54 | 176 / 226 | 59% | 2.89 | 238 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 7.05 | 29 / 29 |
| spleen | 100% | 226.02 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 11.82 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 3.57 | 1 / 1 |
| blood vessel | 100% | 205.63 | 1330 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 100% | 225.69 | 1199 / 1204 | 0% | 0 | 0 / 0 |
| muscle | 98% | 175.39 | 789 / 803 | 0% | 0 | 0 / 0 |
| heart | 97% | 527.13 | 839 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 43% | 184.31 | 399 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 38% | 1.25 | 30 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006351 | Biological process | DNA-templated transcription |
| GO_0071897 | Biological process | DNA biosynthetic process |
| GO_0022414 | Biological process | reproductive process |
| GO_0051726 | Biological process | regulation of cell cycle |
| GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0017053 | Cellular component | transcription repressor complex |
| GO_0003677 | Molecular function | DNA binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | LIN9 |
| Protein name | Lin-9 DREAM MuvB core complex component LIN9 protein Protein lin-9 homolog (HuLin-9) (hLin-9) (Beta subunit-associated regulator of apoptosis) (TUDOR gene similar protein) (Type I interferon receptor beta chain-associated protein) (pRB-associated protein) Alternative protein LIN9 |
| Synonyms | TGS BARA |
| Description | FUNCTION: Acts as a tumor suppressor. Inhibits DNA synthesis. Its ability to inhibit oncogenic transformation is mediated through its association with RB1. Plays a role in the expression of genes required for the G1/S transition. . |
| Accessions | Q6P142 ENST00000460719.5 ENST00000481685.1 H0Y322 ENST00000366808.6 H7C4T7 L8E9Q2 ENST00000328205.9 [Q5TKA1-2] ENST00000359525.2 ENST00000681046.1 [Q5TKA1-1] B1B047 C9J5J4 Q5TKA1 |
